Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025BloodOpen Access

Young (35 years) matched sibling donors for allogeneic transplantation with post-transplantation cyclophosphamide in patients with secondary acute myeloid leukemia in first complete remission: A study from the ALWP/EBMT

View Full Paper
Ask AI
Bookmark
Share

Authors

ANArnon NaglerAFAllain-Thibeault FerhatYKYener Koç

Discussion

Loading...

Member takes

Overview

Observational analysis shows similar outcomes but higher non-relapse mortality for young haploidentical donors in secondary acute myeloid leukemia patients undergoing HSCT.

Key Points

  • Similar transplantation outcomes were observed between young haploidentical and older matched sibling donors, with higher non-relapse mortality in the younger group.
  • The cumulative incidence of day +30 absolute neutrophil count was lower in the young haploidentical donor group at 83.9% compared to 93.8% for older donors.
  • Assessment of graft-versus-host disease incidences revealed similar rates of acute GvHD between both donor types and a lower incidence of extensive chronic GvHD in the young group.
  • Karnofsky performance status below 90 was identified as a poor prognostic factor affecting neutrophil engraftment and non-relapse mortality.

Cite This Study

Nagler et al. (2025) studied this question.

synapsesocial.com/papers/69362f4e4fa91c937236d87fhttps://doi.org/10.1182/blood-2025-4193
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1T cell replete haploidentical transplantation compared to mismatched unrelated allogeneic transplantation with post-transplantation cyclophosphamide in patients with secondary acute myeloid leukemia in first complete remission: A study from the ALWP/EBMT2025
  2. 2Matched sibling donors still provide superior survival outcomes in older patients with AML in second complete remission. a study from the global committee and the acute leukemia working party of the european society for blood and marrow transplantation2025
  3. 3Better outcomes with haploidentical than matched sibling donors for adult AML patients allo-transplanted in CR with detectable MRD: A study from the global committee and the ALWP of the EBMT.2025 · 1 citations
  4. 4Donor‐Related Factors Affecting Haploidentical HSCT Outcomes in Acute Leukemia: A Single‐Center Retrospective Cohort Study of a Modified Combination of Anti‐Thymocyte Globulin and Post‐Transplant Cyclophosphamide2026
  5. 5Comparison of outcomes in pediatric patients with acute leukemia undergoing allogeneic HLA-haploidentical hematopoietic stem cell transplantation (HSCT) after in vitro a/b T- and CD19-cell depletion or In Vivo administration of post-transplant cyclophosphamide: An EBMT pediatric working party study2025